Idiopathic Thrombocytopenic Purpura

• EMA approval · 2026-07-21
  EMA Authorised: Eltrombopag Accord (eltrombopag olamine) — Accord Healthcare S.L.U.

  EMA authorises Eltrombopag Accord for idiopathic thrombocytopenic purpura (ITP).

• EMA approval · 2026-02-26
  EMA Authorised: Revolade (eltrombopag) — Novartis Europharm Limited

  The EMA authorized Revolade (eltrombopag). It covers idiopathic thrombocytopenic purpura and aplastic anaemia.

• EMA approval · 2026-01-08
  EMA Authorised: Wayrilz (rilzabrutinib) — Sanofi B.V.

  The EMA authorised Wayrilz (rilzabrutinib) for idiopathic thrombocytopenic purpura, designated as an orphan medicine in the EU.

• EMA approval · 2025-10-15
  EMA Authorised: Nplate (romiplostim) — Amgen Europe B.V.

  EMA authorised marketing of Nplate (romiplostim) for idiopathic thrombocytopenic purpura (ITP) in the European Union. The decision confirms …

• EMA approval · 2025-05-28
  EMA Authorised: Privigen (human normal immunoglobulin (IVIg)) — CSL Behring GmbH

  Privigen (human normal immunoglobulin IVIg) has been authorised by the EMA for multiple indications. The listed therapeutic areas include id…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2019-10-17
  FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)

  The FDA approved a supplemental application for NPLATE (romiplostim) from Amgen.